BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37103095)

  • 1.
    Pepe P; Pepe L; Tamburo M; Marletta G; Savoca F; Pennisi M; Fraggetta F
    In Vivo; 2023; 37(3):1318-1322. PubMed ID: 37103095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Biopsy in Men High Risk for Prostate Cancer:
    Pepe P; Pennisi M
    Clin Genitourin Cancer; 2023 Dec; 21(6):639-642. PubMed ID: 37394379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
    Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
    Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic accuracy of
    Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L
    BJU Int; 2019 Nov; 124 Suppl 1():42-49. PubMed ID: 31287613
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection Rate of
    Pepe P; Pepe L; Cosentino S; Ippolito M; Pennisi M; Fraggetta F
    Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Utility of
    Kalapara AA; Ballok ZE; Ramdave S; O'Sullivan R; Ryan A; Konety B; Grummet JP; Frydenberg M
    Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

  • 12. Ability of
    Yi N; Wang Y; Zang S; Yang L; Liu H; Sun H; Wang L; Wang F
    Cancer Med; 2023 Mar; 12(6):7140-7148. PubMed ID: 36519688
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Liu C; Liu T; Zhang Z; Zhang N; Du P; Yang Y; Liu Y; Yu W; Li N; Gorin MA; Rowe SP; Zhu H; Yan K; Yang Z
    J Nucl Med; 2020 Sep; 61(9):1314-1319. PubMed ID: 32034111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PRIMARY Score: Using Intraprostatic
    Emmett L; Papa N; Buteau J; Ho B; Liu V; Roberts M; Thompson J; Moon D; Sheehan-Dare G; Alghazo O; Agrawal S; Murphy D; Stricker P; Hope TA; Hofman MS
    J Nucl Med; 2022 Nov; 63(11):1644-1650. PubMed ID: 35301240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Evaluation of
    Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
    Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?
    Demirci E; Kabasakal L; Şahin OE; Akgün E; Gültekin MH; Doğanca T; Tuna MB; Öbek C; Kiliç M; Esen T; Kural AR
    Nucl Med Commun; 2019 Jan; 40(1):86-91. PubMed ID: 30395048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of metastatic disease on
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
    Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
    Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.